Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:GU5's Return-on-Tangible-Asset is ranked better than 62.5% of 120
companies
in the Medical Distribution industry
Industry Median: 2.305
vs FRA:GU5: 3.69
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Asset Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Asset Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
FRA:GU5 vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Asset vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 8.73% mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Return-on-Tangible-Asset of 8.73% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 45% above median its historical median of 6.04. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Asset has ranged from 3.69 to 8.84. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #45 out of 120 companies in the Medical Distribution industry, placing it in the top 37.5%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Asset too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Asset of 8.73% is 45% above median its 10-year median of 6.04. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 8.84. The Medical Distribution industry median Return-on-Tangible-Asset is 2.31. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.73% is 278.7% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #45 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #45 out of 120 companies for Return-on-Tangible-Asset. This puts Guangzhou Baiyunshan Pharmaceutical Holdings Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.31. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.73% is 278.7% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own Return-on-Tangible-Asset has ranged from 3.69 to 8.84 over the past decade. While the company's 10-year median is 6.04 vs. the industry median of 2.31, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Asset of 8.73% is 278.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Asset is 8.73%, which is 45% above median its own 10-year median of 6.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.40, compared to a current price of €1.73 — trading 27.9% below its estimated fair value. The current Return-on-Tangible-Asset is 8.73%, which is 45% above median its 10-year median of 6.04 and 278.7% above the Medical Distribution industry median of 2.31. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Return-on-Tangible-Asset is 8.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.73 is trading 27.9% below its estimated GF Value™ of €2.40.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for FRA:GU5:
Return-on-Tangible-Asset: 8.73% (45% above median its 10-year median of 6.04)
GF Value™: €2.40 vs. price of €1.73 (27.9% below fair value)
Industry Position: 278.7% above the Medical Distribution median (#45 of 120)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
74GF Score
Get the complete analysis for FRA:GU5
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
